Chapter 15: Antidepressant Drugs

Antidepressant Drugs begins by exploring the biochemical theories of depression, specifically the monoamine hypothesis which posits that deficiencies in serotonin, norepinephrine, and dopamine—along with dysregulation of second messenger systems and brain-derived neurotrophic factor (BDNF)—underlie depressive symptoms. The text details the evolution and mechanism of action for major drug classes, beginning with Selective Serotonin Reuptake Inhibitors (SSRIs), which are currently the first-line treatment due to their safety profile, despite potential side effects like sexual dysfunction, apathy syndrome, and serotonin toxicity. The discussion expands to include Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Norepinephrine Dopamine Reuptake Inhibitors (NDRIs) such as bupropion, distinguishing their unique therapeutic benefits, such as smoking cessation support and a lower incidence of sexual side effects. Older generations of medications are rigorously examined, including Tricyclic Antidepressants (TCAs), which function by blocking amine reuptake but carry significant risks for anticholinergic toxicity and lethal cardiac arrhythmias in overdose scenarios. The chapter also covers Monoamine Oxidase Inhibitors (MAOIs), explaining their irreversible inhibition of enzymes that metabolize neurotransmitters and the critical necessity of dietary restrictions to prevent tyramine-induced hypertensive crises. Furthermore, the text reviews novel antidepressants like mirtazapine and vilazodone, as well as nontraditional approaches involving scopolamine and nutritional supplementation. Significant attention is given to nursing implications, including the monitoring of therapeutic lag time, managing discontinuation syndromes, and assessing the black box warning regarding increased suicidality in adolescents and young adults during the initiation of therapy.